SynthesisImmunologic research2022
Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review.
Synthesis in Immunologic research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Neuromuscular diseases associated with COVID-19 vaccines: a systematic review and pooled analysis of 258 patients.BMC neurology · 2023Pooled it
- From Immunization to Autoimmunity: A Deep Dive Into Post-COVID-19 Vaccine Reactions-A Narrative Review.Health science reports · 2026Article
- Autoimmune manifestations recorded after SARS-CoV-2 vaccination.Clinical and experimental vaccine research · 2025Article
- New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination.Internal medicine (Tokyo, Japan) · 2025Article
- Serious adverse drug reactions associated with anti-SARS-CoV-2 vaccines and their reporting trends in the EudraVigilance database.Scientific reports · 2025Observational
- Impact of COVID-19 on Guillain Barre Syndrome (GBS) insights from an Iranian referral center.Frontiers in neurology · 2025Article
- Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.Therapeutic advances in neurological disorders · 2025Article
- Article
- A risk science perspective on vaccines.Risk analysis : an official publication of the Society for Risk Analysis · 2024Article
- [Epidemiological and clinical aspects of Guilain-Barré syndrome, 2012-2022].Revista medica del Instituto Mexicano del Seguro Social · 2024Observational
- Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS).Vaccines · 2024Article
- Neurological Disorders following COVID-19 Vaccination.Vaccines · 2023Review
- Observational
- Guillain-Barré syndrome associated with SARS-CoV-2 vaccination: how is it different? a systematic review and individual participant data meta-analysis.Clinical and experimental vaccine research · 2023Article
- Guillain-Barré syndrome following the second dose of COVID AstraZeneca vaccine in a 78-year-old male: a case report from Nepal.Annals of medicine and surgery (2012) · 2023Article
- COVID-19 Vaccination and Alcohol Consumption: Justification of Risks.Pathogens (Basel, Switzerland) · 2023Review
- Guillain-Barré Syndrome Following the First Dose of Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV.Cureus · 2023Article
- Distal Chronic Inflammatory Demyelinating Polyneuropathy Following COVID-19 Vaccination in a Patient with Solitary Plasmacytoma: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2023Review
- COVID-19: a modern trigger for Guillain-Barre syndrome, myasthenia gravis, and small fiber neuropathy.Frontiers in neuroscience · 2023Review
- Diagnostic Pitfalls in Guillain-Barré Syndrome: Case Report and Literature Review.Children (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the beginning of worldwide vaccination against coronavirus disease 2019 (COVID-19), studies have reported a possible association between vaccination and Guillain-Barré syndrome (GBS). In this regard, we conducted a systematic review assessing different demographic, clinical, and neurophysiological aspects of patients with GBS following immunization with COVID-19 vaccines. A comprehensive search of PubMed, Web of Science, Scopus, and Google Scholar was performed. Articles in English between January 2020 and November 2021 were included. Data on demographics, clinical characteristics, vaccines information, treatment approaches, and outcomes were extracted. The data of a total of 88 patients out of 41 studies was included. The mean age of patients was 58.7 ± 16.6 years and 55 cases (62.5%) were male. AstraZeneca was the most-reported vaccine associated with GBS with 52 cases (59.1%) followed by Pfizer with 20 cases (22.7%). GBS occurred after the first dose of vaccination in 70 cases (79.5%). The mean time interval between vaccination and symptom onset was 13.9 ± 7.4 days. Limb weakness (47.7%), sensory disturbance (38.6%), and facial weakness (27.3%) were the most common reported symptoms, respectively. Albuminocytologic dissociation was seen in 65% of patients who underwent lumbar puncture (n = 65). Acute inflammatory demyelinating polyradiculopathy was the most common GBS subtype, which was reported in 38 patients (43.2%). While one-fifth of patients underwent intubation (n = 17), a favorable outcome was achieved in the majority of subjects (n = 46, 63%). Overall, a small rise in GBS incidence, following various COVID-19 vaccines, was observed. Notably, 85% of affected individuals experienced at least a partial recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.